Iraj Sharifi
Overview
Explore the profile of Iraj Sharifi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
1348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jafarzadeh A, Gurjar D, Bodhale N, Jafarzadeh S, Nemati M, Sharifi I, et al.
Cytokine
. 2023 Dec;
174:156461.
PMID: 38065046
Establishing a balance between Th1 and Th2 subsets and M1- and M2-type macrophages is essential for the control of Leishmania infection. The suppressors of cytokine secretion (SOCS) proteins, particularly SOCS1...
12.
Ghatee M, Sharifi I, Mohammadi N, Moghaddam B, Kohansal M
Front Public Health
. 2023 Nov;
11:1236552.
PMID: 38026324
Introduction: Cutaneous leishmaniasis (CL) is a prevalent debilitating disease in many countries, particularly in Iran, the Middle East, North Africa, and South America. Bam County is the most important highly...
13.
Mohebali M, Edrissian G, Akhoundi B, Shirzadi M, Hassanpour G, Behkar A, et al.
Iran J Parasitol
. 2023 Oct;
18(3):279-293.
PMID: 37886254
Background: Visceral leishmaniasis (VL) is one of the most important neglected tropical diseases. The zoonotic form of VL is endemic in some areas of Iran. We aimed to determine the...
14.
Salarkia E, Mehdipoor M, Molaakbari E, Khosravi A, Sazegar M, Salari Z, et al.
Heliyon
. 2023 Oct;
9(10):e20430.
PMID: 37810809
The advancements in nanoscience have brought attention to the potential of utilizing nanoparticles as carriers for oral insulin administration. This study aims to investigate the effectiveness of synthesized polymeric mesoporous...
15.
Derakhshani A, Sharifi I, Salarkia E, Keyhani A, Agha Kuchak Afshari S, Iranmanesh B, et al.
PLoS One
. 2023 Sep;
18(9):e0291321.
PMID: 37682979
This study aimed to investigate the in vitro and in silico antileishmanial activity of azacitidine (AZA) on Leishmania major promastigotes and amastigotes. The in silico method was used to evaluate...
16.
Salarkia E, Sharifi I, Keyhani A, Oliaee R, Khosravi A, Sharifi F, et al.
PLoS One
. 2023 Sep;
18(9):e0291322.
PMID: 37682934
A significant barrier to optimal antileishmanial treatment is low efficacy and the emergence of drug resistance. Multiple approaches were used to monitor and assess crocin (a central component of saffron)...
17.
Hajhosseini M, Sharifi I, Bamorovat M, Karamoozian A, Amanizadeh A, Agha Kuchak Afshari S
Environ Monit Assess
. 2023 Aug;
195(9):1132.
PMID: 37653110
Microbiological monitoring of the air hospital is essential for prevention and control, due to the possible airborne route of infection transmission, especially in high-risk wards. This study aimed to monitor...
18.
Sharifi I, Khosravi A, Aflatoonian M, Salarkia E, Bamorovat M, Karamoozian A, et al.
Front Public Health
. 2023 May;
11:1091709.
PMID: 37188278
Iran has invariably been under the growing public health threat of cutaneous leishmaniasis (CL), a significant barrier to local development that hinders the prevention and control efforts toward eliminating the...
19.
Mirzaei M, Sharifi I, Mohammad-Rafi F, Anjomshoa M, Abiri A, Moqaddari A, et al.
J Inorg Biochem
. 2023 May;
245:112245.
PMID: 37167732
Leishmaniasis caused by the protozoan Leishmania presents a severe illness, principally in tropical and subtropical areas. Antileishmanial metal complexes, like Glucantime® with proven activity, are routinely studied to probe their...
20.
Bahraminejad S, Pardakhty A, Sharifi I, Keyhani A, Salarkia E, Ranjbar M
Heliyon
. 2023 Apr;
9(4):e15308.
PMID: 37096004
Leishmaniasis as a widespread neglected vector-borne protozoan disease is a major public health concern in endemic areas due to 12 million people affected worldwide and 60,000 deaths annually. Several problems...